BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 2445335)

  • 1. Differential ability of tumor-unique and cross-reactive antigen(s) on two murine hepatoma cell lines to induce Lyt-1+2- T cells responsible for in vivo protective immunity.
    Shima J; Yoshioka T; Kosugi A; Ogata M; Fujiwara H; Hamaoka T; Ueda S; Kato S
    Biken J; 1987 Mar; 30(1):1-8. PubMed ID: 2445335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Helper T cells against tumor-associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses.
    Fujiwara H; Yoshioka T; Shima J; Kosugi A; Itoh K; Hamaoka T
    J Immunol; 1986 Apr; 136(7):2715-9. PubMed ID: 3005417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
    Fujiwara H; Fukuzawa M; Yoshioka T; Nakajima H; Hamaoka T
    J Immunol; 1984 Sep; 133(3):1671-6. PubMed ID: 6205091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Demonstration of intratumoral infiltration of tumor-specific Lyt-1+2- T cells mediating delayed-type hypersensitivity response and in vivo protective immunity.
    Tomita S; Fujiwara H; Yamane Y; Sano S; Nakajima H; Izumi Y; Arai H; Kawanishi Y; Tsuchida T; Hamaoka T
    Jpn J Cancer Res; 1986 Feb; 77(2):182-9. PubMed ID: 3082830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specificity of antigens on UV radiation-induced antigenic tumor cell variants measured in vitro and in vivo.
    Hostetler LW; Romerdahl CA; Kripke ML
    Cancer Res; 1989 Mar; 49(5):1207-13. PubMed ID: 2465081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The augmentation of tumor-specific immunity by virus help. II. Enhanced induction of cytotoxic T lymphocyte and antibody responses to tumor antigens by vaccinia virus-reactive helper T cells.
    Shimizu Y; Fujiwara H; Ueda S; Wakamiya N; Kato S; Hamaoka T
    Eur J Immunol; 1984 Sep; 14(9):839-43. PubMed ID: 6236991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-T cell interaction in the induction of delayed-type hypersensitivity (DTH) responses: vaccinia virus-reactive helper T cell activity involved in enhanced in vivo induction of DTH responses and its application to augmentation of tumor-specific DTH responses.
    Takai Y; Kosugi A; Yoshioka T; Tomita S; Fujiwara H; Hamaoka T
    J Immunol; 1985 Jan; 134(1):108-13. PubMed ID: 3155458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced induction of tumor-specific Lyt-1+2- T cell-mediated protective immunity by in vivo administration of interleukin 1.
    Izumi Y; Tsuchida T; Okuno K; Fujiwara H; Hamaoka T
    Jpn J Cancer Res; 1985 Sep; 76(9):863-70. PubMed ID: 3932286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.
    Nakajima H; Fujiwara H; Takai Y; Izumi Y; Sano S; Tsuchida T; Hamaoka T
    J Immunol; 1985 Sep; 135(3):2199-205. PubMed ID: 3894520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Afferent and efferent specificity in the induction and elicitation of parental cross-protective immunity by an immunogenic murine tumor variant: associative recognition of a unique tumor-specific antigen on somatic cell hybrids.
    LeGrue SJ; Ananthaswamy HN; Simcik WJ
    Cancer Res; 1989 Sep; 49(17):4747-51. PubMed ID: 2474372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment of tumor-specific immunotherapy model utilizing vaccinia virus-reactive helper T cell activity.
    Shimizu Y; Hasumi K; Masubuchi K; Okudaira Y
    Eur J Immunol; 1988 Nov; 18(11):1773-8. PubMed ID: 2974424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Murine tumor cell lysis by antibody-dependent macrophage-mediated cytotoxicity using syngeneic monoclonal antibodies.
    Kawase I; Komuta K; Ogura T; Fujiwara H; Hamaoka T; Kishimoto S
    Cancer Res; 1985 Apr; 45(4):1663-8. PubMed ID: 3978634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additional evidence for the augmented induction of tumor-specific resistance in vaccinia virus-primed mice by immunization with vaccinia virus-modulated syngeneic tumor cells.
    Ueda S; Wakamiya N; Wu KS; Kato S; Fujiwara H; Hamaoka T
    Biken J; 1984 Mar; 27(1):1-7. PubMed ID: 6385960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular interactions and the role of interleukin 2 in the expression and induction of immunity against a syngeneic murine sarcoma.
    Chou T; Shu S
    J Immunol; 1987 Sep; 139(6):2103-9. PubMed ID: 2957448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced TNP-reactive helper T cell activity and its utilization in the induction of amplified tumor immunity that results in tumor regression.
    Fujiwara H; Moriyama Y; Suda T; Tsuchida T; Shearer GM; Hamaoka T
    J Immunol; 1984 Mar; 132(3):1571-7. PubMed ID: 6198397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The augmentation of tumor-specific immunity by virus help. I. Demonstration of vaccinia virus-reactive helper T cell activity involved in enhanced induction of cytotoxic T lymphocyte and antibody responses.
    Fujiwara H; Shimizu Y; Takai Y; Wakamiya N; Ueda S; Kato S; Hamaoka T
    Eur J Immunol; 1984 Feb; 14(2):171-5. PubMed ID: 6199215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment of a tumor-specific immunotherapy model utilizing TNP-reactive helper T cell activity and its application to the autochthonous tumor system.
    Fujiwara H; Aoki H; Yoshioka T; Tomita S; Ikegami R; Hamaoka T
    J Immunol; 1984 Jul; 133(1):509-14. PubMed ID: 6233375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmentation of antitumor immune response by trinitrophenyl (TNP)-reactive helper T-cells: enhanced induction of tumor-specific Lyt-1+2- T-cell-mediated delayed-type hypersensitivity from spleen cells of tumor-bearing mice by TNP helpers.
    Suda T; Fujiwara H; Mizushima Y; Shearer GM; Hamaoka T
    J Natl Cancer Inst; 1986 Dec; 77(6):1267-72. PubMed ID: 2948049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a cloned ultraviolet radiation (UV)-induced suppressor T cell line that is capable of inhibiting anti-UV tumor-immune responses.
    Roberts LK
    J Immunol; 1986 Mar; 136(5):1908-16. PubMed ID: 2936813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct responses of two hepatocellular carcinoma cell lines of a similar origin to immunotherapies targeting regulatory or effector T cells.
    Nagayama Y; Hase W; Motoyoshi Y; Saitoh O; Sogawa R; Nakao K
    Oncol Rep; 2007 May; 17(5):1269-73. PubMed ID: 17390075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.